Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs,

Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. Owing to various reasons, conventional pharmacological interventions have been severely restricted in terms of accessing protein targets of pathological significance. However, researchers engaged in developing bifunctional protein degrader-based interventions claim that this upcoming class of medicinal compounds possess the capability to access the part of the eukaryotic proteome that was previously considered undruggable. The science behind this innovation revolves around the use of specially designed small molecules that are capable of recruiting the ubiquitin-proteasome system (UPS) to selectively eliminate a target protein, via proteolysis. The applications of this technology in drug discovery are vast. Further, drugs designed / based on this concept are known to demonstrate a remarkable level of selectivity, high potency, oral bioavailability and differentiated pharmacology, when compared to traditional occupancy-based inhibitors. As a result, targeted protein degradation-based therapeutics have generated enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine. The growing popularity and interest in the therapeutic potential of these molecules is evident across modern scientific literature (500+ related articles on NCBI’s PubMed portal), and from social media chatter (4,000+ tweets posted on the platform, Twitter, over the last three years).

The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Over the years, significant progress has been made towards understanding the physiochemical and biological properties of these bifunctional molecules. In fact, a variety of other chemical entities and molecular glues have been developed for the treatment of a variety of clinical conditions, including acute myeloid leukemia, Alzheimer's disease, breast cancer, myelofibrosis, multiple myeloma, Parkinson's disease, prostate cancer, psoriasis, rheumatoid arthritis, and supranuclear palsy. R&D efforts in this field are being supported by novel DNA-encoded libraries and other versatile bioinformatics tools, which are enabling efficient hit discovery and characterization of potential therapeutic leads. So far, investments worth over USD 3.5 billion have been made in this emerging field of research by various private and public investors. In addition, technology developers with expertise in targeted protein degradation are known to have been involved in several big licensing deals. It is also worth mentioning that, in the last 4-5 years, there has been a marked rise in the number of new entrants in this market. Interestingly, several big pharma players are also actively evaluating protein degraders. Although there are no approved protein degrader-based drugs / therapy products in the market yet, we can expect targeted protein degradation to become a major therapeutic modality in the coming decade.

SCOPE OF THE REPORT
The ‘Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics, 2020-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade. The focus of this study is on specially designed small molecule degraders, including degronimids, endosome targeting chimeras (ENDTACs), epichaperome inhibitors, hydrophobic tags, immuno-modulatory imide drugs (IMiDs), lysosome targeting chimeras (LYTACs), molecular glues, photochemically targeting chimeras (PHOTACs), proteolysis targeting chimeras (PROTACs), protein homeostatic modulators, selective androgen receptor degraders (SARDs), selective estrogen receptor degraders (SERDs), specific and non-genetic IAP-dependent protein erasers (SNIPERs), and specific bromodomain and extra-terminal motif (BET) inhibitors and deubiquitinase (DUB) inhibitors. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

A detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s), type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of target protein(s), target enzyme(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted protein degraders.

Elaborate profiles of key players that are engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history.

Brief tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.

A detailed clinical trial analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.

An assessment of the relative experience of key opinion leaders (KOLs) within this domain, (shortlisted based on their involvement in various clinical studies), featuring detailed 2X2 matrices (based on the strength and activeness of KOLs), a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).

An analysis of the partnerships that have been established in the domain, over the period 2014-Q3 2019, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.

An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.

One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for novel technologies designed for the development of targeted protein degraders. Based on the likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2020-2030. The report features likely distribution of the current and forecasted opportunity across [A] type of protein degrader (degronimids, IMiDs, PROTACs, SARDs, SERDs, and specific BET and DUB inhibitors), [B] therapeutic area (inflammatory disorders, neurological disorders, oncological disorders, respiratory disorders, and other therapeutic areas), [C] route of administration (oral, intravenous and others), [D] key contributing technologies and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties associated with the growth of targeted protein degradation market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of targeted protein degradation-based drugs market and its likely evolution in the short-mid term and long term.

Chapter 3 is an introductory chapter that highlights important concepts related to protein homeostasis, including a discussion on the UPS for intracellular protein degradation and turnover. It presents an elaborate discussion on the structure and function of ubiquitin, various components of the UPS and key steps involved in the UPS-based protein degradation. Further, the chapter provides an overview of the concept of targeted protein degradation, including details on various protein degraders and their associated pathways and mechanisms of action. The chapter also includes a discussion on the historical evolution, importance, advantages and challenges related to the use of targeted protein degradation as a therapeutic principle. In addition, the chapter describes the key growth drivers and roadblocks related to targeted protein degraders, offering insights on the upcoming trends in the domain.

Chapter 4 includes information on more than 85 targeted protein degraders that are currently being evaluated in different stages of development (both clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules based on their types of protein degraders (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phases of development (clinical, preclinical, and discovery stage) of product candidates, target indications, key therapeutic areas, types of target proteins, target enzymes (if available), target signaling pathways (if available), mechanisms of action (if available), types of therapies (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any). Further, the chapter provides information on drug developer(s), highlighting their year of establishment, location of headquarters and company size. In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted protein degraders.

Chapter 5 features elaborate profiles of key players that are engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products). Each company profile includes a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history. Further, the chapter includes tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.

Chapter 6 provides a detailed clinical trial analysis of completed, ongoing and planned studies of various targeted protein degraders. The analysis highlights the key trends associated with these clinical studies across various parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.

Chapter 7 provides an analysis of KOLs in the field of targeted protein degradation. It features a comprehensive list of principal investigators / study directors of different clinical trials, along with information related to the affiliated research institutes. The chapter features a schematic representation of a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criteria, which was based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).

Chapter 8 presents a detailed publication analysis of more than 210 peer-reviewed, scientific articles that have been published since 2017, highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on novel protein degraders, potential target proteins, target disease indications, and analyses based on various relevant parameters, such as year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.

Chapter 9 provides information on funding instances and investments that have been made within the targeted protein degradation domain. The chapter includes details on various types of investments (such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies in the period 2014-Q3 2019, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 10 features an elaborate analysis and discussion of partnerships / collaborations that have been established in this domain in the period 2014-Q3 2019. It includes a brief description of various types of partnership models (such as research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to targeted protein degraders. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 11 features a comprehensive market forecast, highlighting the future potential of novel technologies designed for the development of targeted protein degraders till 2030, based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future. In addition, we estimated the likely distribution of the current and forecasted opportunity across [A] type of protein degrader (degronimids, PROTACs, SARDs / SERDs, specific BET and DUB inhibitors, and other degraders), [B] therapeutic area (neurodegenerative disorders, oncological disorders, and other therapeutic areas), [C] route of administration (oral, intravenous and others), and [D] key geographical regions (North America, Europe and Asia-Pacific).

Chapter 12 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report



LIST OF COMPANIES AND ORGANIZATIONS

The following companies / institutes / government bodies and organizations have been mentioned in this report.

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 5AM Ventures
2. 6 Dimensions Capital
3. AbbVie
4. Abingworth
5. Abramson Cancer Center, University of Pennsylvania
6. Advantech Capital
7. Aisling Capital
8. AJU IB Investment
9. Alexandria Venture Investments
10. Alfred Berg
11. Almac Discovery
12. Altitude Life Science Ventures
13. AM Capital
14. Amgen
15. Amsterdam UMC
16. Amzak Health
17. AnnJi Pharmaceutical
18. ARCH Venture Partners
19. ARENSIA Exploratory Medicine
20. Arpeggio Biosciences
21. Artios Pharma
22. Arvinas
23. Astex Pharmaceuticals
24. AstraZeneca
25. Atlas Venture
26. Aurigene Discovery Technologies
27. Avista Pharma Solutions
28. Barbara Ann Karmanos Cancer Center
29. Bayer
30. Beactica
31. BeiGene
32. Beijing Huarong Sangel Venture Capital
33. Bellco Capital
34. Bessemer Venture Partners
35. Beverly Hills Cancer Center
36. BeyondSpring Pharmaceuticals
37. Biogen
38. BioRap Technologies
39. BioStrategics Consulting
40. BioTheryX
41. Boehringer Ingelheim
42. Borun Investment
43. Boston Biochem
44. Boxer Capital, Tavistock Group
45. Bristol-Myers Squibb
46. BVF Partners
47. C4 Therapeutics
48. Calico
49. Calico Labs
50. Cambridge Breast Cancer Research Unit, University of Cambridge
51. Cambridge Enterprise
52. Cambridge Innovation Capital
53. Cambridge Stem Cell Institute
54. Canaan Partners
55. Cancer Research Technology
56. Capital Pathology
57. Captor Therapeutics
58. Cardinal Partners
59. Carmot Therapeutics
60. Casdin Capital
61. Cedilla Therapeutics
62. Celgene
63. CellCentric
64. Cellzome
65. Center for Molecular and Biomolecular Informatics
66. Centre for Clinical Hematology, Queen Elizabeth Hospital
67. Chemical Computing Group
68. Chengdu Dingjian
69. Children's Hospital of Philadelphia, University of Pennsylvania
70. China Construction Bank
71. Chugai Pharmaceuticals
72. Clarivate Analytics
73. Cobro Ventures
74. Constellation Pharmaceuticals
75. Cormorant Asset Management
76. Cosmo Bio
77. Covance
78. Cowen Private Investments
79. Crede Capital Group
80. CSOP Asset Management
81. Cullgen
82. Cyclofluidic
83. Daegu Gyeongbuk Medical Innovation Foundation
84. Dana-Farber Cancer Institute
85. Deerfield Management
86. Dorian Therapeutics
87. Duke University
88. EG Capital
89. Eisai
90. Elan Science One
91. Eli Lilly
92. Emeriti Bio
93. Epiphron Capital Group
94. Erasmus University Medical Center
95. Eriksam Invest Aktiebolag
96. Eshelman Ventures
97. Eternal Thrive
98. European Molecular Biology Laboratory
99. Everbright Sun Hung Kai
100. Evotec
101. Feinberg School of Medicine, Northwestern University
102. Fidelity Biosciences
103. FIMECS
104. Florida Cancer Specialists & Research Institute
105. FORMA Therapeutics
106. Fosun
107. Fox Chase Cancer Center
108. Franklin Templeton Investments
109. Fred Hutchinson Cancer Research Center
110. G1 Therapeutics
111. Genentech
112. Gilead Sciences
113. Gladiator
114. GlaxoSmithKline
115. GNI Group
116. GV
117. GVK Biosciences
118. H. Lee Moffitt Cancer Center and Research Institute
119. Haisco Pharmaceutical
120. Handelsbanken Fonder
121. Harvard Medical School
122. Hatteras Venture Partners
123. HBM Healthcare Investments
124. HealthCap
125. HealthCare Ventures
126. Hermed Alpha
127. HighLight Capital
128. Hillhouse Capital
129. Hinova Pharmaceuticals
130. HitGen
131. Holy Cross Hospital
132. Honghui Capital
133. Horizon Discovery
134. Horizons Venture
135. Hybrigenics Pharma
136. IDEAYA Biosciences
137. ImmunoLogik
138. Imperial Innovations
139. INIM Pharma
140. Innovate UK
141. Institute of Cancer and Genomic Sciences, University of Birmingham
142. Institute of Immunology and Experimental Therapy, Polish Academy of Sciences
143. InventisBio
144. Invus
145. IP Group
146. Jules Bordet Institute
147. Juno Therapeutics
148. Kronos Bio
149. Kymera Therapeutics
150. Lang Sheng Investment
151. Lilly Ventures
152. Ling Long Private Equity
153. Longwood Fund
154. Lumira Capital
155. Macroceutics
156. Manchester Cancer Research Centre
157. Massachusetts General Hospital
158. Mayo Clinic
159. McGill University
160. MD Anderson Cancer Center
161. MedImmune Ventures
162. Medivir
163. Memorial Sloan Kettering Cancer Center
164. Merck
165. Mirae Asset Capital
166. Mission Therapeutics
167. Mitobridge
168. Moonstone Investments
169. Morningside Ventures
170. Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute
171. Mountain Group Partners
172. MRC Cambridge Stem Cell Institute
173. MRL Ventures Fund
174. Mubadala Ventures
175. Nanologica
176. National Cancer Institute
177. National Centre for Research and Development
178. National Institute of Genetics
179. New China Asset Management
180. New Enterprise Associates
181. New Leaf Venture Partners
182. Nextech Invest
183. NIHR CRUK Experimental Cancer Medicine Centre
184. Nordic Cross
185. Novartis
186. Novartis Institutes for BioMedical Research
187. Novartis-Berkeley Center for Proteomics and Chemistry Technologies
188. Nuevolution
189. Nurix Therapeutics
190. Nyenburgh Investment Partners
191. Oerth Bio
192. Ohio State University
193. Olema Pharmaceuticals
194. Omega Funds
195. Oncternal Therapeutics
196. OrbiMed
197. Oriental Securities Capital
198. Oxford Finance
199. PamGene
200. Parexel
201. Pelago Bioscience
202. Perceptive Advisors
203. Pfizer
204. Pin Therapeutics
205. Plexium
206. Polaris Partners
207. PolyProx Therapeutics
208. Profacgen
209. Progenra
210. Promega
211. Prostate Cancer Foundation
212. Proteostasis Therapeutics
213. Providence Investment
214. PTC Therapeutics
215. Pudong Innotek
216. Queen’s University
217. RA Capital Management
218. Radius Health
219. Regeneron Pharmaceuticals
220. Robert-Bosch-Hospital, Stuttgart
221. Roche
222. Rock Springs Capital Management
223. Roswell Park Cancer Institute
224. RT Capital
225. Samus Therapeutics
226. Sanofi Genzyme
227. Sarah Cannon Research Institute
228. Sequoia Capital China
229. Servier
230. Shanghai Broad Resources Investment Management
231. Shanghai Free Trade Zone Equity Fund
232. Shenzhen Sangel Venture Capital
233. Shenzhen Sangel Zhichuang Investment
234. Sirona Capital
235. Sitryx
236. Sofinnova Partners
237. Solar Capital
238. Songhe Capital
239. South Texas Accelerated Research Therapeutics
240. SR One
241. Stanford Women’s Cancer Center
242. Stephenson Cancer Center
243. Suzhou Broad Resources
244. Suzhou Pioneer Pharmaceutical
245. SV Health Investors
246. SV Torch
247. Swedbank Robur
248. Sygnature Discovery
249. Takeda Pharmaceutical
250. Tavistock Life Sciences
251. Tetralogic Pharmaceuticals
252. The Column Group
253. The DMS Group
254. The Institute of Cancer Research
255. The Kraft Group
256. The Michael J. Fox Foundation
257. The Netherlands Cancer Institute
258. The Rockefeller University
259. The Royal Marsden NHS Foundation Trust
260. The Silverstein Foundation for Parkinson’s with GBA
261. Theravance Biopharma
262. Third Rock Ventures
263. Tianyi Hong Kong Development
264. Tokalas
265. Trinitas Capital
266. UbiQ Bio
267. Ubiquigent
268. UCLA Jonsson Comprehensive Cancer Center
269. Ultragenyx
270. Unionen
271. Unity Biotechnology
272. Universitair Ziekenhuis Leuven
273. University Hospital Erlangen
274. University Medical Center Groningen
275. University of California, Berkeley
276. University of Chicago
277. University of Dundee
278. University of Illinois
279. University of Kentucky
280. University of Liverpool
281. University of North Carolina at Chapel Hill
282. University of Oxford
283. University of Strathclyde
284. University of Tennessee Research Foundation
285. University of Toledo
286. University of Washington
287. Vagelos College of Physicians and Surgeons, Columbia University
288. Verastem Oncology
289. Versant Ventures
290. Vertex Pharmaceuticals
291. Vicore Pharma
292. Vida Ventures
293. Vividion Therapeutics
294. Weill Medical College of Cornell University
295. Woodford Patient Capital Trust
296. Wroclaw Research Center EIT+
297. WuXi AppTec
298. Wyeth
299. X-Chem
300. Xios Therapeutics
301. Yale University
302. Yissum
303. Yuanhe Holding
304. Yuansheng Venture Capital
305. Zenopharm